Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 2 Sell Rating(s), 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.30 (50.00% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015WallachBeth CapitalLower Price TargetBuy$8.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015ZacksDowngradeNeutral -> Underperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2015Piper JaffrayReiterated RatingOverweight$7.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015RBC CapitalInitiated CoverageSector Perform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2015BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014BMO Capital MarketsReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit SuisseInitiated CoverageUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2014WallachBeth CapitalLower Price TargetBuy$9.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2014Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/15/2013WallachBeth CapitalInitiated CoverageBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013Leerink SwannReiterated RatingOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013Jefferies GroupReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2013Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/3/2013Cowen and CompanyInitiated CoverageMarket Perform$4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2013Credit SuisseLower Price TargetUnderperform$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2013Piper JaffrayLower Price TargetOverweight$11.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2013Leerink SwannReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2013Piper JaffrayReiterated RatingOverweight$9.00 -> $12.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/22/2013 forward)